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1 M 60 Extremity Deep Tail-like 24.8 2 + + DOD
2 F 90 Extremity Superficial Solid 32 2 - - CDF
3 F 70 Extremity Superficial Tail-like 8.3 2 - - CDF
4 M 78 Extremity Deep Tail-like 144.5 2 - - CDF
5 M 75 Trunk Superficial Tail-like 40.5 2 - - CDF
Supplementary Table 1. Clinical characteristics of patients with myxofibrosarcoma who were included in the array analyses.
No. Gender Age Diagnosis
1 M 64 Lipoma
2 F 65 Lipoma
3 F 71 GCTTS
4 M 83 GCTTS
5 F 69 Schwannoma
Supplementary Table 2. Characteristics of non-sarcoma 
patients who were included in the array analyses.
Abbreviation: GCTTS: Giant cell tumor of tendon sheath
No. Gender Age Disease-state
1 F 56 Healthy individual
2 F 58 Healthy individual
3 F 54 Healthy individual
4 F 34 Healthy individual
5 F 33 Healthy individual
6 F 42 Healthy individual
7 F 62 Healthy individual
8 F 64 Healthy individual
9 M 32 Healthy individual
Supplementary Table 3. Characteristics of healthy 
individuals who were included in the array analyses.
Supplementary Table 4–6
miRNA P value Fold change
MFS vs CONT MFS vs NON MFS vs CONT MFS vs NON
miR-642a 5.3E-02 8.8E-02 3.0 2.1
miR-1260b 5.4E-03 3.6E-03 5.1 2.3
miR-4286 1.6E-03 5.63.E-02 4.1 2.7
miR-4313 4.4E-03 6.6E-02 4.1 1.7
Supplementary Table 6. Differentially expressed miRNAs in MFS patients vs Healthy individuals or  benign tumor 
patients
Supplementary Table 4. Differentially expressed miRNAs in MFS patients vs age-matched patients with benign tumor 
patients (NON; p<0.005).
Supplementary Table 5. Differentially expressed miRNAs in MFS patients vs Healthy individuals (CONT; p<0.005)
See Supplementary Data 2 File
See Supplementary Data 2 File
Supplementary Table 9. Candidates of miR-1260b target genes (selected from Supplementary Table 7 and 
Supplementary Table 8).
Supplementary Table 7,8,9




1260b AGO2-NC Input-1260b Input-NC
ENSG00000256683 ZNF350 zinc finger protein 350 3174 125 110 493
ENSG00000067066 SP100 SP100 nuclear antigen 1682 337 57 297
ENSG00000172046 USP19 ubiquitin specific peptidase 19 996 98 21 46
ENSG00000167384 ZNF180 zinc finger protein 180 565 27 10 22
ENSG00000186300 ZNF555 zinc finger protein 555 465 10 6 29
ENSG00000169957 ZNF768 zinc finger protein 768 431 80 5 11
ENSG00000182175 RGMA repulsive guidance molecule family member a 317 29 7 17
ENSG00000158805 ZNF276 zinc finger protein 276 270 6 5 24
ENSG00000184226 PCDH9 protocadherin 9 222 27 13 27
ENSG00000004700 RECQL RecQ like helicase 196 9 44 95
ENSG00000235109 ZSCAN31 zinc finger and SCAN domain containing 31 181 25 14 32
ENSG00000121274 PAPD5 PAP associated domain containing 5 174 24 10 39
ENSG00000083817 ZNF416 zinc finger protein 416 146 27 17 42
ENSG00000076641 PAG1 phosphoprotein membrane anchor with glycosphingolipid microdomains 1 106 14 23 49
ENSG00000165280 VCP valosin containing protein 102 24 22 45
See Supplementary Data 2 File
Supplementary Table 7. Downregulated genes determined by a combination of Input-IP after transfection with miR-
1260b compared to miR-NC in NFs (< 2-fold decrease).
Supplementary Table 8. Upregulated genes determined by a combination of AGO2-IP after transfection with miR-




































































































































Supplementary Figure 1. The miRNA expression levels in MFS tumor tissues and controls (normal
muscle). All of these four candidates (miR-642a, miR-1260b, miR-4286 and miR-4313) were not



























































































































Supplementary Figure 2. The cellular miRNA expression levels in MFS cells and hMSCs. The
expression levels of miR-1260b, miR-642a, and miR-4286 were not significantly upregulated in MFS cells
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Supplementary Figure 3
Supplementary Figure 3. Full-length blots shown in 
Figure 3C. (A) CD63 (53kDa) and cytochrome-C 






































Supplementary Figure 4. miR-1260b expression levels in the EVs from human serum. (A) Isolation of EVs
using EV-Second method. CD9-positive fractions (5-7 fractions) were recognized as the EV-rich portion. (B)
The collected EVs from fraction 5 confirmed by TEM (left) and ZetaSizer (right) (C) miR-1260b expression





































































































Supplementary Figure 5. Invasion assay. (A) NMFH1 and NMFH2 cells educated by NF cells-derived EVs
and control PBS did not show significant difference in cellular invasion. Data are mean S.D. (n = 3 in each
group) Scale bar = 50 µm. (B) NF cells-derived EVs educated NMFH1 and NMFH2 cells did not stimulate
cellular invasion of MFS cells. Left, NMFH-1; right, NMFH-2. Data are mean  S.D. (n = 3 in each group)
Scale bar = 200 µm. N.S., not significant; Student’s t test.
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